Celcuity CELC
NASDAQ CELC
$72.10 -3.03 (-4.03%)
At close: Oct 2, 2026 · 4:00 PM EDT

Celcuity (CELC) Gains from Sales and Divestitures (2021)

Updated

Celcuity (CELC) posted Gains from Sales and Divestitures of -$263.00 for FY2021.

Analysis

Celcuity (CELC) Gains from Sales and Divestitures (2021) Analysis & Trends

  • The FY2021 figure stands as the highest annual Gains from Sales and Divestitures since FY2018.
  • Business Quant data shows CELC's Gains from Sales and Divestitures at $3,000 in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Celcuity 3.53 Bn 3.53 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 -526.00
Mar 31, 2021 263.00
API Access

Celcuity Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CELC&period=max&api_key=YOUR_API_KEY